BRAF and metastatic malignant neoplasm in the lymph nodes: The BRAF V600E mutation was associated with extrathyroidal extension, lymph node metastases, and a higher rate of biochemical incomplete response to therapy (HR = 2.43; 95% CI: 1.21–5.23; P = 0.016).